<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36969239</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta.</ArticleTitle><Pagination><StartPage>1135815</StartPage><MedlinePgn>1135815</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1135815</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1135815</ELocationID><Abstract><AbstractText>Licensed COVID-19 vaccines ameliorate viral infection by inducing production of neutralizing antibodies that bind the SARS-CoV-2 Spike protein and inhibit viral cellular entry. However, the clinical effectiveness of these vaccines is transitory as viral variants escape antibody neutralization. Effective vaccines that solely rely upon a T cell response to combat SARS-CoV-2 infection could be transformational because they can utilize highly conserved short pan-variant peptide epitopes, but a mRNA-LNP T cell vaccine has not been shown to provide effective anti-SARS-CoV-2 prophylaxis. Here we show a mRNA-LNP vaccine (MIT-T-COVID) based on highly conserved short peptide epitopes activates CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses that attenuate morbidity and prevent mortality in HLA-A*02:01 transgenic mice infected with SARS-CoV-2 Beta (B.1.351). We found CD8<sup>+</sup> T cells in mice immunized with MIT-T-COVID vaccine significantly increased from 1.1% to 24.0% of total pulmonary nucleated cells prior to and at 7 days post infection (dpi), respectively, indicating dynamic recruitment of circulating specific T cells into the infected lungs. Mice immunized with MIT-T-COVID had 2.8 (2 dpi) and 3.3 (7 dpi) times more lung infiltrating CD8<sup>+</sup> T cells than unimmunized mice. Mice immunized with MIT-T-COVID had 17.4 times more lung infiltrating CD4<sup>+</sup> T cells than unimmunized mice (7 dpi). The undetectable specific antibody response in MIT-T-COVID-immunized mice demonstrates specific T cell responses alone can effectively attenuate the pathogenesis of SARS-CoV-2 infection. Our results suggest further study is merited for pan-variant T cell vaccines, including for individuals that cannot produce neutralizing antibodies or to help mitigate Long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Carter, Huang, Liu, Liang, Lin, Peng, McKay, Dimitrakakis, Hsu, Tat, Saenkham-Huntsinger, Chen, Kaseke, Gaiha, Xu, Griffiths, Tam, Tseng and Gifford.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Pinghan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Yuejin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Paulo J C</ForeName><Initials>PJC</Initials><AffiliationInfo><Affiliation>Acuitas Therapeutics, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Bi-Hung</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Cell Biology, and Anatomy, The University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKay</LastName><ForeName>Lindsay G A</ForeName><Initials>LGA</Initials><AffiliationInfo><Affiliation>National Emerging Infectious Diseases Laboratories, Department of Microbiology, Boston University School of Medicine, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimitrakakis</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Cell Biology, and Anatomy, The University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tat</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saenkham-Huntsinger</LastName><ForeName>Panatda</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jinjin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Tufts University, Medford, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaseke</LastName><ForeName>Clarety</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaiha</LastName><ForeName>Gaurav D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiaobing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Tufts University, Medford, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Emerging Infectious Diseases Laboratories, Department of Microbiology, Boston University School of Medicine, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Ying K</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Acuitas Therapeutics, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chien-Te K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Cell Biology, and Anatomy, The University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, The University of Texas Medical Branch, Galveston, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gifford</LastName><ForeName>David K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T cell vaccine</Keyword><Keyword MajorTopicYN="N">challenge study</Keyword><Keyword MajorTopicYN="N">mRNA-LNP</Keyword><Keyword MajorTopicYN="N">peptide vaccine</Keyword></KeywordList><CoiStatement>DG and BC are founders of Think Therapeutics. PL and YT are employees of Acuitas Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>3</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36969239</ArticleId><ArticleId IdType="pmc">PMC10033589</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1135815</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walsh EE, Frenck RW, Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. . Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med (2020) 383(25):2439&#x2013;50. doi:&#xa0;10.1056/NEJMoa2027906</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med (2021) 384(5):403&#x2013;16. doi:&#xa0;10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: Viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol (2021) 21(10):626&#x2013;36. doi:&#xa0;10.1038/s41577-021-00592-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00592-1</ArticleId><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, et al. . SARS-CoV-2 omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol (2022) 7(8):1161&#x2013;79. doi:&#xa0;10.1038/s41564-022-01143-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01143-7</ArticleId><ArticleId IdType="pmc">PMC9352574</ArticleId><ArticleId IdType="pubmed">35798890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wu S, Wu B, Yang Q, Chen A, Li Y, et al. . SARS-CoV-2 omicron strain exhibits potent capabilities for immune evasion and viral entrance. Signal Transduct Target Ther (2021) 6(1):430. doi:&#xa0;10.1038/s41392-021-00852-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00852-5</ArticleId><ArticleId IdType="pmc">PMC8678971</ArticleId><ArticleId IdType="pubmed">34921135</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai H, Chan JF, Yuen TT, Yoon C, Hu JC, Wen L, et al. . Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine (2021) 73:103643. doi:&#xa0;10.1016/j.ebiom.2021.103643</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103643</ArticleId><ArticleId IdType="pmc">PMC8530107</ArticleId><ArticleId IdType="pubmed">34689086</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez DR, Sch&#xe4;fer A, Leist SR, de la Cruz G, West A, Atochina-Vasserman EN, et al. . Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice. Science (2021) 373(6558):991&#x2013;8. doi:&#xa0;10.1126/science.abi4506</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi4506</ArticleId><ArticleId IdType="pmc">PMC8899822</ArticleId><ArticleId IdType="pubmed">34214046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AA, van Doremalen N, Greaney AJ, Andersen H, Sharma A, Starr TN, et al. . Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science (2022) 377(6606):eabq0839. doi:&#xa0;10.1126/science.abq0839</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq0839</ArticleId><ArticleId IdType="pmc">PMC9273039</ArticleId><ArticleId IdType="pubmed">35857620</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Carter B, Bricken T, Jain S, Viard M, Carrington M, et al. . Computationally optimized SARS-CoV-2 MHC class I and II vaccine formulations predicted to target human haplotype distributions. Cell Syst (2020) 11(2):131&#x2013;144.e6. doi:&#xa0;10.1016/j.cels.2020.06.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2020.06.009</ArticleId><ArticleId IdType="pmc">PMC7384425</ArticleId><ArticleId IdType="pubmed">32721383</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan A, Rossin EJ, Kaseke C, Park RJ, Khatri A, Koundakjian D, et al. . Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell (2021) 184(17):4401&#x2013;4413.e10. doi:&#xa0;10.1016/j.cell.2021.06.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.06.029</ArticleId><ArticleId IdType="pmc">PMC8241654</ArticleId><ArticleId IdType="pubmed">34265281</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Carter B, Gifford DK. Predicted cellular immunity population coverage gaps for SARS-CoV-2 subunit vaccines and their augmentation by compact peptide sets. Cell Syst (2021) 12(1):102&#x2013;107.e4. doi:&#xa0;10.1016/j.cels.2020.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2020.11.010</ArticleId><ArticleId IdType="pmc">PMC7691134</ArticleId><ArticleId IdType="pubmed">33321075</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Dimitrakakis A, Carter B, Gifford DK. Maximum n-times coverage for vaccine design, International conference on learning representations, ICLR. (2022).</Citation></Reference><Reference><Citation>Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H, et al. . Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol (2008) 180(1):309&#x2013;18. doi:&#xa0;10.4049/jimmunol.180.1.309</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.1.309</ArticleId><ArticleId IdType="pubmed">18097032</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, L&#xf6;wer M, et al. . Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature (2017) 547(7662):222&#x2013;6. doi:&#xa0;10.1038/nature23003</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature23003</ArticleId><ArticleId IdType="pubmed">28678784</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, et al. . The immune epitope database (IEDB): 2018 update. Nucleic Acids Res (2018) 47(D1):D339&#x2013;D343. doi:&#xa0;10.1093/nar/gky1006</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1006</ArticleId><ArticleId IdType="pmc">PMC6324067</ArticleId><ArticleId IdType="pubmed">30357391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotturi MF, Assarsson E, Peters B, Grey H, Oseroff C, Pasquetto V, et al. . Of mice and humans: How good are HLA transgenic mice as a model of human immune responses? Immunome Res (2009) 5:3. doi:&#xa0;10.1186/1745-7580-5-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-7580-5-3</ArticleId><ArticleId IdType="pmc">PMC2702351</ArticleId><ArticleId IdType="pubmed">19534819</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft NP, Smith SA, Pickering J, Sidney J, Peters B, Faridi P, et al. . Most viral peptides displayed by class I MHC on infected cells are immunogenic. Proc Natl Acad Sci U.S.A. (2019) 116(8):3112&#x2013;7. doi:&#xa0;10.1073/pnas.1815239116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815239116</ArticleId><ArticleId IdType="pmc">PMC6386720</ArticleId><ArticleId IdType="pubmed">30718433</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakiboneka R, Mugaba S, Auma BO, Kintu C, Lindan C, Nanteza MB, et al. . Interferon gamma (IFN-&#x3b3;) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens. Vaccine (2019) 37(1):113&#x2013;22. doi:&#xa0;10.1016/j.vaccine.2018.11.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.11.024</ArticleId><ArticleId IdType="pmc">PMC6290111</ArticleId><ArticleId IdType="pubmed">30459072</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, et al. . SARS-CoV-2 omicron virus causes attenuated disease in mice and hamsters. Nature (2022) 603(7902):687&#x2013;92. doi:&#xa0;10.1038/s41586-022-04441-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04441-6</ArticleId><ArticleId IdType="pmc">PMC8942849</ArticleId><ArticleId IdType="pubmed">35062015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari P, Rothan HA, Natekar JP, Stone S, Pathak H, Strate PG, et al. . Neuroinvasion and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice. Viruses (2021) 13(1):132. doi:&#xa0;10.3390/v13010132</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010132</ArticleId><ArticleId IdType="pmc">PMC7832889</ArticleId><ArticleId IdType="pubmed">33477869</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol (2022) 23(2):186&#x2013;93. doi:&#xa0;10.1038/s41590-021-01122-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, Hsu NS, et al. . The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. iScience (2021) 24(11):103353. doi:&#xa0;10.1016/j.isci.2021.103353</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103353</ArticleId><ArticleId IdType="pmc">PMC8552693</ArticleId><ArticleId IdType="pubmed">34729465</ArticleId></ArticleIdList></Reference><Reference><Citation>Redd AD, Nardin A, Kared H, Bloch EM, Pekosz A, Laeyendecker O, et al. . CD8+ T cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. medRxiv (2021) 12:2021. doi:&#xa0;10.1101/2021.02.11.21251585</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.02.11.21251585</ArticleId><ArticleId IdType="pmc">PMC8083629</ArticleId><ArticleId IdType="pubmed">34322559</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini O, Rokach L, Itchaki G, Braester A, Shvidel L, Goldschmidt N, et al. . Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica (2022) 107(3):625&#x2013;34. doi:&#xa0;10.3324/haematol.2021.279196</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2021.279196</ArticleId><ArticleId IdType="pmc">PMC8883569</ArticleId><ArticleId IdType="pubmed">34320789</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitmann JS, Bilich T, Tandler C, Nelde A, Maringer Y, Marconato M, et al. . A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature (2022) 601(7894):617&#x2013;22. doi:&#xa0;10.1038/s41586-021-04232-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04232-5</ArticleId><ArticleId IdType="pmc">PMC8791831</ArticleId><ArticleId IdType="pubmed">34814158</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardieck IN, van der Sluis TC, van der Gracht ETI, Veerkamp DMB, Behr FM, van Duikeren S, et al. . A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection. Nat Commun (2022) 13(1):3966. doi:&#xa0;10.1038/s41467-022-31721-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31721-6</ArticleId><ArticleId IdType="pmc">PMC9267705</ArticleId><ArticleId IdType="pubmed">35803932</ArticleId></ArticleIdList></Reference><Reference><Citation>Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. . SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol (2021) 6(59):eabj1750. doi:&#xa0;10.1126/sciimmunol.abj1750</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abj1750</ArticleId><ArticleId IdType="pmc">PMC9268159</ArticleId><ArticleId IdType="pubmed">34035118</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelow B, Mao T, Klein J, Song E, Menasche B, Omer SB, et al. . Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci Immunol (2021) 6(64):eabl4509. doi:&#xa0;10.1126/sciimmunol.abl4509</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4509</ArticleId><ArticleId IdType="pmc">PMC9047536</ArticleId><ArticleId IdType="pubmed">34623900</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, Str&#xe5;lin K, Gorin JB, Olsson A, et al. . Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell (2020) 183(1):158&#x2013;168.e14. doi:&#xa0;10.1016/j.cell.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Shree T. Shree T. Can B cell-deficient patients rely on COVID-19 vaccine-induced T-cell immunity? Br J Haematol (2022) 197(6):659&#x2013;661. doi:&#xa0;10.1111/bjh.18210</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.18210</ArticleId><ArticleId IdType="pmc">PMC9111762</ArticleId><ArticleId IdType="pubmed">35412649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingstad-Bakke B, Lee W, Chandrasekar SS, Gasper DJ, Salas-Quinchucua C, Cleven T, et al. . Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc Natl Acad Sci U.S.A. (2022) 119(20):e2118312119. doi:&#xa0;10.1073/pnas.2118312119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2118312119</ArticleId><ArticleId IdType="pmc">PMC9171754</ArticleId><ArticleId IdType="pubmed">35561224</ArticleId></ArticleIdList></Reference><Reference><Citation>Matchett WE, Joag V, Stolley JM, Shepherd FK, Quarnstrom CF, Mickelson CK, et al. . Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. J Immunol (2021) 207(2):376&#x2013;379. doi: 10.4049/jimmunol.2100421</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100421</ArticleId><ArticleId IdType="pmc">PMC8516699</ArticleId><ArticleId IdType="pubmed">34193597</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, et al. . Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity (2016) 44(6):1379&#x2013;91. doi:&#xa0;10.1016/j.immuni.2016.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.05.006</ArticleId><ArticleId IdType="pmc">PMC4917442</ArticleId><ArticleId IdType="pubmed">27287409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajnik RL, Plante JA, Liang Y, Alameh MG, Tang J, Bonam SR, et al. . Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 omicron and delta variants in preclinical models. Sci Transl Med (2022) 14(662):eabq1945. doi:&#xa0;10.1126/scitranslmed.abq1945</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abq1945</ArticleId><ArticleId IdType="pmc">PMC9926941</ArticleId><ArticleId IdType="pubmed">36103514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ, Katovich Hurley C. Frequencies of HLA-A2 alleles in five U.S. population groups. predominance of A*02011 and identification of HLA-A*0231. Hum Immunol (2000) 61(3):334&#x2013;40. doi:&#xa0;10.1016/s0198-8859(99)00155-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0198-8859(99)00155-x</ArticleId><ArticleId IdType="pubmed">10689125</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. . Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med (2021) 385(18):1680&#x2013;9. doi:&#xa0;10.1056/NEJMoa2109908</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109908</ArticleId><ArticleId IdType="pmc">PMC10662971</ArticleId><ArticleId IdType="pubmed">34379914</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira PMN, Mendes-de-Almeida DP, Bertollo Gomes Porto V, Crespo Cordeiro C, Vitiello Teixeira G, Saraiva Pedro R, et al. . Brazillian VITT investigative collaboration group. vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil. Vaccine (2022) 40(33):4788&#x2013;95. doi:&#xa0;10.1016/j.vaccine.2022.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.014</ArticleId><ArticleId IdType="pmc">PMC9212666</ArticleId><ArticleId IdType="pubmed">35779962</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . In the wake of the pandemic: Preparing for long COVID (2021) (Accessed August 14, 2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">33877759</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. . Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis (2022), 76(3):e487&#x2013;e490. doi:&#xa0;10.1093/cid/ciac722</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>